A recent study led by the University of Southern California (USC) has uncovered a strong connection between type 2 diabetes ...

Researchers from the University of Melbourne and Murdoch Children's Research Institute (MCRI) have developed a blood test ...

The blood test measures two subtypes of tau and amyloid proteins, which can indicate the presence of amyloid plaque in the ...

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), ...

RIT biomedical engineering professor Cristian Linte and his research team are integrating artificial intelligence techniques ...

Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker for Alzheimer’s. Previously, the only FDA-approved methods for ...

The FDA noted the risk of false positive test results from Lumipulse, which could lead to inappropriate diagnosis and unnecessary treatment. FDA Commissioner Marty Makary, M.D., MPH, wrote in a ...

It can be based solely on clinical presentation or more rigorous diagnostic tests, such as culturing of the infectious agent, microscopy, biochemical screens and molecular methods. Many SARS-CoV-2 ...

New Imaging Technologies (NIT) announces the release of the SenS 1920 CameraLink, now available for purchase, starting May 2025. This Full HD SWIR camera delivers exceptional image quality and low ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) ...